Tango Therapeutics, Inc. Earnings Dividend

Tango Therapeutics, Inc.’s revenue fell -100% since last year same period to $0Mn in the Q2 2026. On a quarterly growth basis, Tango Therapeutics, Inc. has generated NaN% jump in its revenue since last 3-months.

Tango Therapeutics, Inc.’s net profit fell -42.44% since last year same period to $-55.34Mn in the Q2 2026. On a quarterly growth basis, Tango Therapeutics, Inc. has generated -21.59% fall in its net profits since last 3-months.

Tango Therapeutics, Inc.’s net profit margin fell -Inf% since last year same period to -Inf% in the Q2 2026. On a quarterly growth basis, Tango Therapeutics, Inc. has generated NaN% jump in its net profit margins since last 3-months.

Tango Therapeutics, Inc.’s earning per share (EPS) estimates for the current quarter stand at -0.34 - a -9.68% fall from last quarter’s estimates.

Tango Therapeutics, Inc.’s earning per share (EPS) estimates for the current year stand at -0.34.

Tango Therapeutics, Inc.’s earning per share (EPS) fell -5.71% since last year same period to -0.37 in the Q2 2026. This indicates that the Tango Therapeutics, Inc. has generated -5.71% annual rate of fall in its earning per share (EPS) in the last 4 quarters.